The role of gut hormones and the hypothalamus in appetite regulation.

The World Health Organisation has estimated that by 2015 approximately 2.3 billion adults will be overweight and more than 700 million obese. Obesity is associated with an increased risk of diabetes, cardiovascular events, stroke and cancer. The hypothalamus is a crucial region for integrating signals from central and peripheral pathways and plays a major role in appetite regulation. In addition, there are reciprocal connections with the brainstem and higher cortical centres. In the arcuate nucleus of the hypothalamus, there are two major neuronal populations which stimulate or inhibit food intake and influence energy homeostasis. Within the brainstem, the dorsal vagal complex plays a role in the interpretation and relaying of peripheral signals. Gut hormones act peripherally to modulate digestion and absorption of nutrients. However, they also act as neurotransmitters within the central nervous system to control food intake. Peptide YY, pancreatic polypeptide, glucagon-like peptide-1 and oxyntomodulin suppress appetite, whilst ghrelin increases appetite through afferent vagal fibres to the caudal brainstem or directly to the hypothalamus. A better understanding of the role of these gut hormones may offer the opportunity to develop successful treatments for obesity. Here we review the current understanding of the role of gut hormones and the hypothalamus on food intake and body weight control.

[1]  J Mayer,et al.  Regulation of Food Intake and Obesity , 1967, Science.

[2]  G. P. Smith,et al.  Cholecystokinin decreases food intake in rats. , 1973, Journal of comparative and physiological psychology.

[3]  B. Vialettes,et al.  Low Plasma Levels of Pancreatic Polypeptide in Obesity , 1980, Diabetes.

[4]  V. Mutt,et al.  Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides , 1980, Nature.

[5]  S. Woods,et al.  Regulation of food intake and body weight in insulin. , 1981, Diabetologia.

[6]  S. Leibowitz,et al.  Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat , 1981, Physiology & Behavior.

[7]  G. P. Smith,et al.  C-terminal octapeptide of cholecystokinin decreases food intake in man. , 1981, The American journal of clinical nutrition.

[8]  J. Crawley,et al.  Rapid development of tolerance to the behavioural actions of cholecystokinin , 1983, Nature.

[9]  S. Bloom,et al.  Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. , 1983, The Journal of clinical endocrinology and metabolism.

[10]  P. Schneider,et al.  Suppression of weight gain by glucagon in obese Zucker rats. , 1984, Experimental and molecular pathology.

[11]  P S Kalra,et al.  Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. , 1984, Endocrinology.

[12]  S. Woods,et al.  Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. , 1984, The American journal of physiology.

[13]  R. Jorde,et al.  Fasting and postprandial plasma pancreatic polypeptide (PP) levels in obesity. , 1984, International journal of obesity.

[14]  J M Polak,et al.  Human distribution and release of a putative new gut hormone, peptide YY. , 1985, Gastroenterology.

[15]  I. Goldfine,et al.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. , 1985, The Journal of clinical investigation.

[16]  S. Leibowitz,et al.  Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion , 1985, Peptides.

[17]  W. Pardridge,et al.  Human Blood—Brain Barrier Insulin Receptor , 1985, Journal of neurochemistry.

[18]  J. E. Morley,et al.  Peptide YY (PYY), a poteny orexigenic agent , 1985, Brain Research.

[19]  S. Leibowitz,et al.  Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity , 1986, Peptides.

[20]  K. Pienta,et al.  Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. , 1988, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[21]  K. Polonsky,et al.  Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. , 1988, The Journal of clinical investigation.

[22]  Terry D. Lee,et al.  A new molecular form of PYY: Structural characterization of human PYY(3–36) and PYY(1–36) , 1989, Peptides.

[23]  D. Whitcomb,et al.  Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. , 1990, The American journal of physiology.

[24]  D. Porte,et al.  Localization of insulin receptor mRNA in rat brain by in situ hybridization. , 1990, Endocrinology.

[25]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[26]  P. Gross,et al.  Circumventricular organ capillaries. , 1992, Progress in brain research.

[27]  S. Woods,et al.  Inhibition of hypothalamic neuropeptide Y gene expression by insulin. , 1992, Endocrinology.

[28]  E. Theodorsson,et al.  Plasma concentrations of regulatory peptides in obseity following modified sham feeding (MSF) and a liquid test meal , 1992, Regulatory Peptides.

[29]  N. Geary,et al.  Glucagon acts in the liver to control spontaneous meal size in rats. , 1993, The American journal of physiology.

[30]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[31]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[32]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[33]  Steven L. Cohen,et al.  Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.

[34]  S. Wank Cholecystokinin receptors. , 1995, The American journal of physiology.

[35]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[36]  M. Apfelbaum,et al.  Gastric distension, hunger and energy intake after balloon implantation in severe obesity. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[37]  M. Pelleymounter,et al.  Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.

[38]  D. Drucker,et al.  Induction of intestinal epithelial proliferation by glucagon-like peptide 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Brubaker,et al.  Proglucagon processing in islet and intestinal cell lines , 1996, Regulatory Peptides.

[40]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[41]  W. Banks,et al.  Leptin enters the brain by a saturable system independent of insulin , 1996, Peptides.

[42]  L. Tartaglia,et al.  Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice , 1996, Cell.

[43]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[44]  J. Little,et al.  Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary‐adrenal activity , 1997, Clinical endocrinology.

[45]  D. Thompson,et al.  Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons , 1997, Neuroscience.

[46]  T. Ogihara,et al.  Tissue-Specific and Glucose-Dependent Expression of Receptor Genes for Glucagon and Glucagon-Like Peptide-1 (GLP-1) , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[47]  D. Schoeller,et al.  Entrainment of the diurnal rhythm of plasma leptin to meal timing. , 1997, The Journal of clinical investigation.

[48]  R. Darnell,et al.  Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Schwartz,et al.  Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. , 1997, The American journal of physiology.

[50]  P. J. Larsen,et al.  Hypothalamic CART is a new anorectic peptide regulated by leptin , 1998, Nature.

[51]  G M Steil,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Diurnal and Ultradian Rhythmicity of Plasma Leptin: Effects of Gender and Adiposity* , 2022 .

[52]  A. Kelley,et al.  Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. , 1998, The Journal of pharmacology and experimental therapeutics.

[53]  O. Kolterman,et al.  Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin , 1998, Diabetes Care.

[54]  C. Plata-salamán,et al.  Disordered food intake and obesity in rats lacking cholecystokinin A receptors. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[55]  S. Bloom,et al.  A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. , 1998, Endocrinology.

[56]  J. Rehfeld,et al.  The new biology of gastrointestinal hormones. , 1998, Physiological reviews.

[57]  M. Fujimiya,et al.  Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice☆ , 1999, Peptides.

[58]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[59]  H. Herzog,et al.  Regional distribution of Y‐receptor subtype mRNAs in rat brain , 1999, The European journal of neuroscience.

[60]  G. Schwartz,et al.  Gut vagal afferent lesions increase meal size but do not block gastric preload-induced feeding suppression. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[61]  G. Colditz,et al.  The disease burden associated with overweight and obesity. , 1999, JAMA.

[62]  D. Drucker Glucagon-like Peptide 2 , 1999, Trends in Endocrinology & Metabolism.

[63]  M. Schwartz,et al.  Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. , 1999, Diabetes.

[64]  G. Schwartz,et al.  The role of gastrointestinal vagal afferents in the control of food intake: current prospects. , 2000, Nutrition.

[65]  N. Morin,et al.  Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. , 2000, Endocrinology.

[66]  S. Woods,et al.  Central nervous system control of food intake , 2000, Nature.

[67]  M. Tschöp,et al.  Ghrelin induces adiposity in rodents , 2000, Nature.

[68]  Min-Seon Kim,et al.  Investigation of the melanocyte stimulating hormones on food intake Lack of evidence to support a role for the melanocortin-3-receptor , 2000, Brain Research.

[69]  Yue Feng,et al.  Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass , 2000, Nature Genetics.

[70]  上野 尚彦 Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice , 2000 .

[71]  S. Woods,et al.  Amylin: a novel action in the brain to reduce body weight. , 2000, Endocrinology.

[72]  B. Wisse,et al.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.

[73]  D L Hay,et al.  Oxyntomodulin inhibits food intake in the rat. , 2001, Endocrinology.

[74]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[75]  M. Nakazato,et al.  A role for ghrelin in the central regulation of feeding , 2001, Nature.

[76]  B. Stoffel‐Wagner Neurosteroid metabolism in the human brain. , 2001, European journal of endocrinology.

[77]  A. Astrup,et al.  A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[78]  G A Colditz,et al.  Impact of overweight on the risk of developing common chronic diseases during a 10-year period. , 2001, Archives of internal medicine.

[79]  S. Bloom,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Evidence of an Orexigenic Role for Cocaine- and Amphetamine-Regulated Transcript after Administration into Discrete Hypothalamic Nuclei , 2022 .

[80]  W. A. Banks,et al.  Anorectic effects of circulating cytokines: role of the vascular blood-brain barrier. , 2001, Nutrition.

[81]  M. Tschöp,et al.  Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. , 2001, European journal of endocrinology.

[82]  N. Vrang,et al.  Glucagon-like peptide containing pathways in the regulation of feeding behaviour , 2001, International Journal of Obesity.

[83]  Y. Taché,et al.  Peripheral ghrelin selectively increases Fos expression in neuropeptide Y – synthesizing neurons in mouse hypothalamic arcuate nucleus , 2002, Neuroscience Letters.

[84]  E. Air,et al.  Acute third ventricular administration of insulin decreases food intake in two paradigms , 2002, Pharmacology Biochemistry and Behavior.

[85]  H. Grill,et al.  The Neuroanatomical Axis for Control of Energy Balance , 2002, Frontiers in Neuroendocrinology.

[86]  J. A. Fernández-Represa,et al.  Peptide YY Secretion in Morbidly Obese Patients Before and After Vertical Banded Gastroplasty , 2002, Obesity surgery.

[87]  Graham M Lord,et al.  Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. , 2002, The Journal of clinical investigation.

[88]  Noboru Murakami,et al.  The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. , 2002, Gastroenterology.

[89]  Zhaohui Feng,et al.  Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats , 2002, Nature Neuroscience.

[90]  D. Thompson,et al.  Expression of the leptin receptor in rat and human nodose ganglion neurones , 2002, Neuroscience.

[91]  R. Brolin,et al.  Bariatric surgery and long-term control of morbid obesity. , 2002, JAMA.

[92]  C. Lawrence,et al.  Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. , 2002, Endocrinology.

[93]  E. Air,et al.  The Catabolic Action of Insulin in the Brain Is Mediated by Melanocortins , 2002, The Journal of Neuroscience.

[94]  E. Dellinger,et al.  Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. , 2002, The New England journal of medicine.

[95]  J. Wilding Neuropeptides and appetite control , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[96]  A. Geliebter,et al.  Amylin, food intake, and obesity. , 2002, Obesity research.

[97]  D. Keire,et al.  Structure and receptor binding of PYY analogs , 2002, Peptides.

[98]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[99]  Mohammad A Ghatei,et al.  Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.

[100]  Mohammad A Ghatei,et al.  Oxyntomodulin suppresses appetite and reduces food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[101]  A. Sahu Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance , 2003, Frontiers in Neuroendocrinology.

[102]  David Grundy,et al.  Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. , 2003, Gastroenterology.

[103]  E. H. Goulding,et al.  Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor , 2003, Nature Neuroscience.

[104]  G. Frost,et al.  Pancreatic polypeptide reduces appetite and food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[105]  J. Holst,et al.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[106]  J. Egan,et al.  GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells , 2003, Diabetes/metabolism research and reviews.

[107]  M. Fujimiya,et al.  Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. , 2003, Gastroenterology.

[108]  J. Holst,et al.  Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety , 2003, Regulatory Peptides.

[109]  J. Holst,et al.  On the Physiology of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[110]  D. Macneil,et al.  Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. , 2004, Endocrinology.

[111]  J. Holst,et al.  Glucagon‐like peptide‐2 inhibits antral emptying in man, but is not as potent as glucagon‐like peptide‐1 , 2004, Scandinavian journal of gastroenterology.

[112]  D. Drucker,et al.  Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. , 2004, Gastroenterology.

[113]  C. Deacon Circulation and Degradation of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[114]  A. G. Roseberry,et al.  Neuropeptide Y-Mediated Inhibition of Proopiomelanocortin Neurons in the Arcuate Nucleus Shows Enhanced Desensitization in ob/ob Mice , 2004, Neuron.

[115]  D. Coleman Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice , 1978, Diabetologia.

[116]  Mohammad A Ghatei,et al.  Peripheral oxyntomodulin reduces food intake and body weight gain in rats. , 2004, Endocrinology.

[117]  H. Herzog,et al.  NPY and Y receptors: lessons from transgenic and knockout models , 2004, Neuropeptides.

[118]  T. Kigoshi,et al.  Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells , 2004, Autonomic Neuroscience.

[119]  H. Jang,et al.  Peptide YY is secreted after oral glucose administration in a gender-specific manner. , 2005, The Journal of clinical endocrinology and metabolism.

[120]  Stephen R. Bloom,et al.  The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway , 2005, Brain Research.

[121]  Y. Tao Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity , 2005, Molecular and Cellular Endocrinology.

[122]  D. Drucker,et al.  Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. , 2005, Endocrinology.

[123]  S. Bloom,et al.  Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. , 2005, The Journal of clinical endocrinology and metabolism.

[124]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[125]  K. Toshinai,et al.  The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.

[126]  T. Horvath,et al.  Cannabinoids, opioids and eating behavior: The molecular face of hedonism? , 2006, Brain Research Reviews.

[127]  G. Frost,et al.  Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial , 2006, International Journal of Obesity.

[128]  G Hu,et al.  Body mass index and the risk of Parkinson disease , 2006, Neurology.

[129]  A. Klibanski,et al.  Elevated peptide YY levels in adolescent girls with anorexia nervosa. , 2006, The Journal of clinical endocrinology and metabolism.

[130]  S. O’Rahilly,et al.  Genetics of obesity in humans. , 2006, Endocrine reviews.

[131]  R. Cone,et al.  Characterization of leptin-responsive neurons in the caudal brainstem. , 2006, Endocrinology.

[132]  H. Raybould,et al.  Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. , 2007, Endocrinology.

[133]  K. Yaffe,et al.  Body mass index in midlife and risk of Alzheimer disease and vascular dementia. , 2007, Current Alzheimer research.

[134]  C. Koebnick,et al.  Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. , 2007, The Journal of clinical endocrinology and metabolism.

[135]  D. Cummings,et al.  Gastrointestinal regulation of food intake. , 2007, The Journal of clinical investigation.

[136]  J. Holst The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[137]  A. Forbes,et al.  Review article: glucagon‐like peptide 2 – current applications and future directions , 2007, Alimentary pharmacology & therapeutics.

[138]  S. Bloom,et al.  Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass , 2007, Annals of surgery.

[139]  M. Sena-Esteves,et al.  Selective Deletion of Bdnf in the Ventromedial and Dorsomedial Hypothalamus of Adult Mice Results in Hyperphagic Behavior and Obesity , 2007, The Journal of Neuroscience.

[140]  Intragastric balloon for obesity. , 2007, The Cochrane database of systematic reviews.

[141]  D. Ashby,et al.  Recent progress in PYY research—An update report for 8th NPY meeting , 2007, Peptides.

[142]  Sandra Coulon,et al.  Safety of the Ullorex® Oral Intragastric Balloon for the Treatment of Obesity , 2007, Journal of diabetes science and technology.

[143]  T. Reinehr,et al.  Amylin and Its Relation to Insulin and Lipids in Obese Children Before and After Weight Loss , 2007, Obesity.

[144]  S. Swoap,et al.  Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[145]  P. Baldock,et al.  PYY transgenic mice are protected against diet-induced and genetic obesity , 2008, Neuropeptides.

[146]  M. Inoue,et al.  Overweight and obesity trends among Japanese adults: a 10-year follow-up of the JPHC Study , 2008, International Journal of Obesity.

[147]  E. F. Bailey,et al.  A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on "BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat," by Bariohay et al. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[148]  Subhajyoti De,et al.  Common variants near MC4R are associated with fat mass, weight and risk of obesity , 2008, Nature Genetics.

[149]  S. Woods,et al.  A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.

[150]  J. Brüning,et al.  Hormone and glucose signalling in POMC and AgRP neurons , 2009, The Journal of physiology.

[151]  S. Bloom,et al.  Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. , 2009, Endocrinology.

[152]  J. Mindell,et al.  Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012 , 2008, Journal of Epidemiology & Community Health.

[153]  Michael E. Lassman,et al.  Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice , 2009, Diabetes.

[154]  F. Roux,et al.  The relationship of obesity and obstructive sleep apnea. , 2009, Clinics in chest medicine.

[155]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[156]  S. Bloom,et al.  Obesity treatment: novel peripheral targets. , 2009, British journal of clinical pharmacology.

[157]  M. Bessler,et al.  Prospective Study of Gut Hormone and Metabolic Changes After Adjustable Gastric Banding and Roux-en-Y Gastric Bypass , 2009, International Journal of Obesity.

[158]  C. la Vecchia,et al.  The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[159]  S. Woods,et al.  Meal-anticipatory glucagon-like peptide-1 secretion in rats. , 2010, Endocrinology.

[160]  A. Buchman,et al.  Teduglutide, a novel mucosally active analog of glucagon‐like peptide‐2 (GLP‐2) for the treatment of moderate to severe Crohn's disease , 2010, Inflammatory bowel diseases.

[161]  H. Munzberg Leptin-signaling pathways and leptin resistance. , 2010, Forum of nutrition.

[162]  E. Diamandis,et al.  Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. , 2010, Endocrinology.

[163]  J. Hebebrand,et al.  From monogenic to polygenic obesity: recent advances , 2010, European Child & Adolescent Psychiatry.